Combination therapies for the treatment of Alzheimer's disease and related disorders
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
1. A method of treating a disease or condition in a human subject in need thereof comprising co-administering about 16 mg/day or about 20 mg/day of cromolyn or a salt thereof formulated as a dry powder for inhalation, and about 10 mg/day ibuprofen, wherein the disease or condition is Alzheimer's disease; and the cromolyn and ibuprofen, taken together, are therapeutically effective.
2. A method of slowing the progression of a disease or condition in a human subject in need thereof comprising co-administering about 16 mg/day or about 20 mg/day cromolyn or a salt thereof formulated as a dry powder for inhalation, and about 10 mg/day ibuprofen, wherein the disease or condition is Alzheimer's disease; and the cromolyn and ibuprofen, taken together, are therapeutically effective.
3. The method of claim 2 , wherein the cromolyn salt is cromolyn sodium.
4. The method of claim 2 , wherein the cromolyn is formulated for inhalation as a dry powder of less than 3 microns in particle size.
5. The method of claim 4 , wherein the dry powder has a particle size from about 0.5 microns to about 1.5 microns.
6. The method of claim 2 , wherein the ibuprofen is formulated as a pill, capsule, or liquid.
7. The method of claim 2 , wherein the ibuprofen is co-administered orally.
8. The method of claim 2 , wherein the cromolyn and ibuprofen are formulated as an inhalation capsule, pill, oral capsule, or liquid.
9. The method of claim 1 , wherein the cromolyn salt is cromolyn sodium.
10. The method of claim 1 , wherein the cromolyn is formulated for inhalation as a dry powder of less than 3 microns in particle size.
11. The method of claim 10 , wherein the dry powder has a particle size from about 0.5 microns to about 1.5 microns.
12. The method of claim 1 , wherein the ibuprofen is formulated as a pill, capsule, or liquid.
13. The method of claim 1 , wherein the ibuprofen is co-administered orally.
14. The method of claim 1 , wherein the cromolyn and ibuprofen are formulated as an inhalation capsule, pill, oral capsule, or liquid.